MedTrace Logo

Safety of Inhaled Preprandial Human Insulin in Subjects With Diabetes and Asthma

NCT00523042 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2018-09-05

No results posted yet for this study

Summary

This trial is conducted in Europe, Asia, Oceania and the United States of America (USA).

This is a one-year clinical trial to compare the safety of inhaled preprandial human insulin to subcutaneous insulin aspart in subjects with type 1 or 2 diabetes and asthma.

Conditions

Interventions

DRUG

insulin aspart

Treat-to-target dose titration scheme, injection s.c.

DRUG

inhaled human insulin

Treat-to-target dose titration scheme, inhalation.

Sponsors & Collaborators

Principal Investigators

  • Global Clinical Registry (GCR, 1452) · Novo Nordisk A/S

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-08-30
Primary Completion
2008-02-28
Completion
2008-02-28

Countries

  • United States
  • Australia
  • India
  • Malaysia
  • Serbia and Montenegro
  • Slovakia

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00523042 on ClinicalTrials.gov